ArticleOpen medicine (Warsaw, Poland)2026
Specific inhibition of NLRP3 inflammasome by a Smurf1 inhibitor
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Abnormal activation of the NLRP3 inflammasome is associated with various inflammatory diseases, making it a potential therapeutic target. A01 is an inhibitor of Smurf1, its effect on the activation of NLRP3 inflammasome is still unclear and needs further study. Material and methods: Caspase-1 and IL-1β were detected by immunoblotting and ELISA, and (lactate dehydrogenase) LDH release was measured via a specific kit. Immunoprecipitation was used to explore the interaction between NLRP3 and ASC. In a mouse model of alum-induced peritonitis, PECs were collected and analyzed by flow cytometry. In the high-fat diet (HFD) model, blood glucose was measured with a glucometer. Results: A01 inhibited the activation of the NLRP3 inflammasome in macrophages without affecting the activation of AIM2 or NLRC4 inflammasomes. Mechanistically, A01 suppressed NLRP3 inflammasome assembly and activation by disrupting the NLRP3-ASC interaction. Moreover, A01 demonstrated protective effects in mouse models of NLRP3 inflammasome-mediated diseases. Conclusions: A01 specifically suppresses NLRP3 inflammasome activation
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.